Houdini Bio has secured around £1.5 million in grants and pre-seed funding, with SCVC leading the investment.
The company’s software changes therapeutic DNA so that a patient’s own cells do not turn it off.
According to the startup, this solution can increase gene expression by more than ten times compared to competitors.
Houdini Bio just raised about £1.5 million by combining non-dilutive grants, which do not require giving up equity, with an oversubscribed pre-seed round.
SCVC, the venture arm of Science Creates, led the round, while Deep Science Ventures and Cambridge Enterprise VC at the University of Cambridge also participated, according to the company. Houdini Bio develops software that redesigns therapeutic DNA so the body’s defences do not attack it.
